Johnson & Johnson's vector vaccine will contribute 18.3 million doses, and a total 70 million doses of vaccines from Sanofi, Novavax and Valneva will contribute the rest.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
"Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.